Zynex (NASDAQ:ZYXI) Posts Quarterly Earnings Results, Misses Estimates By $0.11 EPS

Zynex (NASDAQ:ZYXI) announced its quarterly earnings results on Tuesday. The company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.11), Zacks reports. Zynex had a return on equity of 13.05% and a net margin of 2.49%.

Zynex Stock Down 2.4 %

ZYXI traded down $0.17 during trading hours on Tuesday, reaching $7.00. 103,296 shares of the stock traded hands, compared to its average volume of 112,010. Zynex has a fifty-two week low of $5.44 and a fifty-two week high of $13.19. The company has a market cap of $222.92 million, a price-to-earnings ratio of 46.67 and a beta of 0.81. The company has a debt-to-equity ratio of 1.66, a current ratio of 3.94 and a quick ratio of 3.15. The firm’s fifty day simple moving average is $7.74 and its two-hundred day simple moving average is $8.02.

Insiders Place Their Bets

In other news, CFO Daniel J. Moorhead sold 10,000 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $7.68, for a total transaction of $76,800.00. Following the completion of the transaction, the chief financial officer now directly owns 19,738 shares in the company, valued at approximately $151,587.84. This represents a 33.63 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have sold 30,000 shares of company stock worth $227,100 in the last quarter. 52.13% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $17.00 target price on shares of Zynex in a research note on Friday, December 6th.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.